Highest-materiality recent filing
PALISADE-4 trial (n=238) did not meet primary endpoint: LS mean change SUDS fasedienol -9.5 vs placebo -11.4 (p=0.427).
Vistagen FY2026 net loss $69.7M; PALISADE-4 topline results expected June 2026
Net loss of $69.7M for FY ended March 31, 2026, vs $51.4M prior year; R&D expense $55.0M.
Vistagen achieves ICH E1 safety exposure minimum for fasedienol; over 1,500 subjects dosed
As of May 31, 2026: over 1,500 subjects with ≥1 dose, 300 with ≥6 months, 100 with ≥12 months exposure to fasedienol.
Vistagen reports positive preliminary OLE data for fasedienol in SAD; well-tolerated up to 12 months
OLE safety (n=341): discontinuation due to AEs 2.6%; no SAEs related to fasedienol; TEAEs >5%: headache 10.9%, URI 11.4%.
Vistagen completes PALISADE-4 Phase 3 patient visits; topline data due Q2 2026
Last patient completed randomized portion of Phase 3 trial for fasedienol acute treatment of social anxiety disorder.
Vistagen gets FDA 'Study May Proceed' letter for refisolone nasal spray in menopausal hot flashes
FDA allows Vistagen to pursue further Phase 2 clinical development of refisolone in U.S. for vasomotor symptoms due to menopause.
Vistagen Q3 FY2026 net loss $18.9M; PALISADE-4 topline expected H1 2026
Net loss $18.9M for quarter ended Dec 31, 2025, vs $14.1M a year ago; R&D expense $14.2M, G&A $5.6M.
Vistagen receives Nasdaq deficiency notice for minimum bid price non-compliance
Received Nasdaq notice on Feb 3, 2026 for non-compliance with $1.00 minimum bid price requirement.
Vistagen's PALISADE-3 Phase 3 study of fasedienol fails primary endpoint in social anxiety disorder
LS mean change from baseline on SUDS score: fasedienol 13.6 (SE 1.54) vs placebo 14.0 (SE 1.51); no statistical significance.
Vistagen reports Q2 FY2026 net loss $19.4M; PALISADE-3 Phase 3 complete, topline due Q4 2025
Net loss $19.4M vs $13.0M YoY; R&D expense $15.9M (up 56% YoY) on PALISADE program.
Vistagen completes PALISADE-3 Phase 3 trial; topline results due by year end
Last patient completed randomized, double-blind, placebo-controlled portion of PALISADE-3 for fasedienol in social anxiety disorder; open-label extension ongoing.
Vistagen reports Q1 net loss of $15.1M; fasedienol Phase 3 data expected Q4 2025 and H1 2026
Net loss $15.1M for fiscal Q1 ended June 30, 2025, vs $10.7M a year ago; R&D expense up to $11.7M.
Vistagen reports FY2025 net loss $51.4M; cash $80.5M; advances PALISADE fasedienol trials
FY2025 net loss $51.4M (vs $29.4M prior year); R&D expenses doubled to $39.4M on fasedienol and PH80 programs.
Vistagen updates fasedienol Phase 3 timelines: PALISADE-3 data Q4 2025, PALISADE-4 H1 2026
PALISADE-3 topline data remains on track for Q4 2025; PALISADE-4 now expected in H1 2026.
Vistagen sued by pro se plaintiffs over alleged misleading clinical trial disclosures
John Cesario and David Preka filed lawsuit on Feb 13, 2025 (Case No. 4:25-cv-01510) in Northern District of California.
Vistagen reports Q3 FY2025 net loss $14.1M; fasedienol Phase 3 progressing
Net loss $14.1M for Q3 ended Dec 31, 2024, vs $6.4M YoY; R&D expense rose to $11.3M from $4.5M.
Vistagen announces positive Phase 2A results for PH284 in cancer cachexia; 71% hunger improvement
PH284 nasal spray demonstrated 71% improvement in subjective feeling of hunger before dinner on Day 7 vs <1% for placebo.
Vistagen enrolls first subject in PALISADE-4 Phase 3 trial of fasedienol for SAD
First subject enrolled in PALISADE-4 Phase 3 trial of fasedienol nasal spray for acute treatment of social anxiety disorder (SAD).
Vistagen Q1 FY2025 net loss $10.7M; PALISADE Phase 3 trials on track for 2025 results
Net loss of $10.7M for Q1 FY2025, up from $6.9M in Q1 FY2024.
Vistagen FY2024 net loss narrows to $29.4M; fasedienol Phase 3 program on track
Net loss of $29.4M for FY2024, down from $59.2M in FY2023; cash and equivalents $119.2M as of March 31, 2024.
PH15 nasal spray demonstrated statistically significant improvement in reaction time versus placebo and caffeine (p<0.001) in sleep-deprived participants.
Vistagen enrolls first patient in PALISADE-3 Phase 3 fasedienol trial for social anxiety disorder
PALISADE-3 is a randomized, double-blind, placebo-controlled study of ~236 adults aged 18–65 with SAD.
Vistagen receives EPO notice of intention to grant AV-101 patent for neuropathic pain
European Patent Office issued Notice of Intention to Grant patent for AV-101 to treat neuropathic pain.
Vistagen reports Q2 net loss $6.6M; fasedienol PALISADE-2 positive; cash $37.6M + $93.5M offering
Net loss $6.6M for Q2 end Sep 30, 2023 vs $17.5M YoY; R&D expense decreased to $3.9M.
Vistagen receives $1.5M from Fuji Pharma for exclusive PH80 negotiation in Japan
Received $1.5M non-refundable payment from Fuji Pharma for exclusive negotiation rights to license PH80 in Japan.
On June 16, 2026, Ms. Margaret FitzPatrick, and on June 17, 2026, Dr. Joanne Curley, each a member of the Board of Directors of Vistagen Therapeutics, Inc. (the “ Company ”), notified the Company of her decision not to stand for re-election at the Company’s 2026 Annual Meeting of Stockholders.
On June 16, 2026, Ms. Margaret FitzPatrick, and on June 17, 2026, Dr. Joanne Curley, each a member of the Board of Directors of Vistagen Therapeutics, Inc. (the “ Company ”), notified the Company of her decision not to stand for re-election at the Company’s 2026 Annual Meeting of Stockholders.
On May 18, 2026 (the “ Effective Date ”), Vistagen Therapeutics, Inc. (the “ Company ”) appointed Angel S. Angelov, M.D., MBA to serve as the Company’s Chief Medical Officer.
On October 24, 2023, Joshua Prince was appointed to serve as the Chief Operating Officer of Vistagen Therapeutics, Inc. (the “ Company ”).
announced the appointment of Ms. Cynthia Anderson, C.P.A., as the Company’s Chief Financial Officer
Ms. Anderson replaces Mr. Jerrold Dotson upon his retirement, effective August 21, 2023
On July 7, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) announced that Jerrold D. Dotson, CPA, Vice President and Chief Financial Officer (principal financial and accounting officer), intends to retire from the Company on or about August 31, 2023.
On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the “Company”) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company’s President and Chief Scientific Officer.
On May 2, 2022, the Board of Directors (the “ Board ”) of VistaGen Therapeutics, Inc. (the “ Company ”), appointed Mr. Reid G. Adler, age 67, as the Company’s Chief Legal Officer.
Dr. Brian J. Underdown notified the Board of Directors (the “ Board ”) of VistaGen Therapeutics, Inc. (the “ Company ”) of his retirement from the Board and all Board committees, effective immediately.
the Board appointed Margaret M. FitzPatrick to serve on the Board.
On July 6, 2021, Mary L. Rotunno J.D. was appointed to serve on the Board of Directors
Max materiality 0.90 · Median 0.57 · Most common event other_material